[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0ZAp8n9gKEHpYcEC8eVpjpyhY7A6ck6lQT7n5buZjG4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University Hospital, Brest",[4],595,false,151,46,249130,30,523,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Pulmonary Embolism",13,{"name":18,"count":19},"Venous Thromboembolism",11,{"name":21,"count":22},"Cystic Fibrosis",9,{"name":24,"count":22},"Pruritus",{"name":26,"count":27},"Chronic Obstructive Pulmonary Disease",8,{"name":29,"count":27},"Polymyalgia Rheumatica",{"name":31,"count":32},"COPD",6,{"name":34,"count":32},"Cerebral Palsy",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04341350","Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation","2025-08","Propofol + analgesic drug",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06765694","Efficacy of One or Two Botulinum Toxin Injections in the Treatment of Chronic Lateral Epicondylalgia: a Retrospective Study (EPITOX)","2025-10-31","Botulinum toxin",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04547504","PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","2025-12-22","Pembrolizumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07408011","Interest of Cryotherapy in Reducing Pain During Radial Arterial Blood Sampling","2026-02-01","Apllication of cream",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05008926","The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients","2026-03-15","Naloxegol",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05997979","Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children","2026-04-05","Capsaicin 8% patch",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04785443","Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy","2026-06-22","ICG",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06495372","Study of the Use of Methoxyflurane vs Placebo in the Management of Pain in Oral and Dental Emergencies in Adults: METODO (METhoxyflurane in ODOntology)","2026-10","Experimenta group (standard of care + Methoxyflurane).",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05458622","3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol","2026-11","Blood sample",{"nctId":82,"briefTitle":83,"date":84,"intervention":80},"NCT05747651","3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2","2026-12-31",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,123,169,203,225,252,270,292,316,337,364,382,404,422,444,465,495,513,536,554,576,594,619,644,669,695,719,740,766,784,802,829,855,891,926,951,977,1004,1022,1040,1065,1089,1112,1140,1158,1185,1210,1235,1260,1278,1303,1329,1356,1374,1392,1418,1436,1462,1480,1506,1530,1554,1579,1604,1630,1648,1682,1706,1730,1753,1771,1789,1814,1841,1874,1899,1923,1950,1974,1992,2018,2044,2070,2095,2121,2144,2169],{"intervention":94,"totalTrials":95,"cells":96},"Low molecular weight heparin",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":121},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":120},"NCT06845423","Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","RECRUITING",[90],"2028-05-16","2028-08-16","2025-05-16",2400,[118,119],"Venous Thromboembolism (VTE)","Post Partum Women",[94],{"trials":122,"activeCount":99},[],{"intervention":80,"totalTrials":124,"cells":125},3,{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":145,"NA":147},{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":99},[],{"trials":133,"activeCount":95,"soonestReadout":79},[134],{"nctId":77,"briefTitle":78,"status":135,"phases":136,"primaryCompletion":79,"completion":79,"start":137,"enrollment":138,"conditions":139,"interventions":141},"ACTIVE_NOT_RECRUITING",[89],"2022-11-29",25,[140],"Systemic Lupus Erythematosus (SLE)",[80,142,143,144],"Urine sample","Saliva sample","Stood sample",{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":168,"soonestReadout":84},[149,160],{"nctId":150,"briefTitle":151,"status":111,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT05384392","Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode",[91],"2027-03","2030-03","2025-03-27",217,[158],"First-episode Psychosis",[80],{"nctId":82,"briefTitle":83,"status":135,"phases":161,"primaryCompletion":84,"completion":84,"start":162,"enrollment":163,"conditions":164,"interventions":165},[],"2023-03-27",10,[140],[80,142,143,166,167],"Stool sample","Tissue sample",2,{"intervention":143,"totalTrials":124,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":183,"NA":185},{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":95,"soonestReadout":79},[179],{"nctId":77,"briefTitle":78,"status":135,"phases":180,"primaryCompletion":79,"completion":79,"start":137,"enrollment":138,"conditions":181,"interventions":182},[89],[140],[80,142,143,144],{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":168,"soonestReadout":84},[187,199],{"nctId":188,"briefTitle":189,"status":111,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT06995040","BREMISS : Brain Resilience Minor Stroke Study",[91],"2027-12-18","2028-12-18","2025-06-18",1000,[196],"Stroke Ischemic",[198],"saliva sample",{"nctId":82,"briefTitle":83,"status":135,"phases":200,"primaryCompletion":84,"completion":84,"start":162,"enrollment":163,"conditions":201,"interventions":202},[],[140],[80,142,143,166,167],{"intervention":142,"totalTrials":168,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":217,"NA":219},{"trials":206,"activeCount":99},[],{"trials":208,"activeCount":99},[],{"trials":210,"activeCount":99},[],{"trials":212,"activeCount":95,"soonestReadout":79},[213],{"nctId":77,"briefTitle":78,"status":135,"phases":214,"primaryCompletion":79,"completion":79,"start":137,"enrollment":138,"conditions":215,"interventions":216},[89],[140],[80,142,143,144],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":95,"soonestReadout":84},[221],{"nctId":82,"briefTitle":83,"status":135,"phases":222,"primaryCompletion":84,"completion":84,"start":162,"enrollment":163,"conditions":223,"interventions":224},[],[140],[80,142,143,166,167],{"intervention":226,"totalTrials":95,"cells":227},"MEOPA",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":248,"NA":250},{"trials":229,"activeCount":99},[],{"trials":231,"activeCount":99},[],{"trials":233,"activeCount":99},[],{"trials":235,"activeCount":95,"soonestReadout":241},[236],{"nctId":237,"briefTitle":238,"status":239,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":247},"NCT07118644","Microbiote's Evolution After Use of Nitrous Oxide on Pediatric Patient Needing Airway Samples","NOT_YET_RECRUITING",[89],"2027-09-06","2025-09-01",40,[245,246],"Respiratory Ilness","Children",[226],{"trials":249,"activeCount":99},[],{"trials":251,"activeCount":99},[],{"intervention":144,"totalTrials":95,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":266,"NA":268},{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":99},[],{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":95,"soonestReadout":79},[262],{"nctId":77,"briefTitle":78,"status":135,"phases":263,"primaryCompletion":79,"completion":79,"start":137,"enrollment":138,"conditions":264,"interventions":265},[89],[140],[80,142,143,144],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":288,"NA":290},{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":95,"soonestReadout":69},[280],{"nctId":67,"briefTitle":68,"status":111,"phases":281,"primaryCompletion":69,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},[89],"2027-06-22","2021-06-22",242,[286],"Thyroid Diseases",[70],{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"intervention":293,"totalTrials":95,"cells":294},"Cannabis oil",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":312,"NA":314},{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":95,"soonestReadout":307},[303],{"nctId":304,"briefTitle":305,"status":239,"phases":306,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":311},"NCT06435299","Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study",[89],"2027-07-01","2025-05-01",218,[24],[293],{"trials":313,"activeCount":99},[],{"trials":315,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":333,"NA":335},{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":95,"soonestReadout":64},[326],{"nctId":62,"briefTitle":63,"status":111,"phases":327,"primaryCompletion":64,"completion":64,"start":328,"enrollment":9,"conditions":329,"interventions":332},[89],"2024-03-05",[330,331],"Neuropathic Pain","Chronic Pain",[65],{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":99},[],{"intervention":338,"totalTrials":95,"cells":339},"Baricitinib 4 MG Oral",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":360,"NA":362},{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":99},[],{"trials":345,"activeCount":99},[],{"trials":347,"activeCount":95,"soonestReadout":352},[348],{"nctId":349,"briefTitle":350,"status":239,"phases":351,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT07279688","Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica",[89],"2028-11-12","2029-06-12","2025-12-12",140,[357],"Polymyalgia Rheumatica (PMR)",[338,359],"Baricitinib 2 MG Oral",{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":99},[],{"intervention":359,"totalTrials":95,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":378,"NA":380},{"trials":367,"activeCount":99},[],{"trials":369,"activeCount":99},[],{"trials":371,"activeCount":99},[],{"trials":373,"activeCount":95,"soonestReadout":352},[374],{"nctId":349,"briefTitle":350,"status":239,"phases":375,"primaryCompletion":352,"completion":353,"start":354,"enrollment":355,"conditions":376,"interventions":377},[89],[357],[338,359],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":400,"NA":402},{"trials":385,"activeCount":99},[],{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":95,"soonestReadout":74},[392],{"nctId":72,"briefTitle":73,"status":111,"phases":393,"primaryCompletion":74,"completion":74,"start":394,"enrollment":395,"conditions":396,"interventions":398},[89],"2024-10-14",192,[397],"Dental Pain and Sensation Disorder",[75,399],"control group (standard of care + placebo).",{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":99},[],{"intervention":399,"totalTrials":95,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":418,"NA":420},{"trials":407,"activeCount":99},[],{"trials":409,"activeCount":99},[],{"trials":411,"activeCount":99},[],{"trials":413,"activeCount":95,"soonestReadout":74},[414],{"nctId":72,"briefTitle":73,"status":111,"phases":415,"primaryCompletion":74,"completion":74,"start":394,"enrollment":395,"conditions":416,"interventions":417},[89],[397],[75,399],{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":440,"NA":442},{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":95,"soonestReadout":59},[432],{"nctId":57,"briefTitle":58,"status":111,"phases":433,"primaryCompletion":59,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},[89],"2026-09-15","2022-03-15",370,[438],"Brain Injuries",[60],{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":461,"NA":463},{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":95,"soonestReadout":54},[454],{"nctId":52,"briefTitle":53,"status":239,"phases":455,"primaryCompletion":54,"completion":456,"start":54,"enrollment":457,"conditions":458,"interventions":460},[89],"2029-11-01",258,[459],"Chronic Respiratory Diseases",[55],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"intervention":466,"totalTrials":95,"cells":467},"Direct Oral Anticoagulants",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":491,"NA":493},{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":99},[],{"trials":475,"activeCount":95,"soonestReadout":480},[476],{"nctId":477,"briefTitle":478,"status":111,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":489},"NCT05198960","AVAJAK: Apixaban\u002FRivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms",[89],"2027-07-13","2022-07-13",1308,[484,485,486,487,488],"Polycythemia Vera","Essential Thrombocythemia","Prefibrotic\u002FEarly Primary Myelofibrosis","JAK2 V617F","High-risk Patients",[466,490],"Low-dose aspirin",{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"intervention":490,"totalTrials":95,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":509,"NA":511},{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":95,"soonestReadout":480},[505],{"nctId":477,"briefTitle":478,"status":111,"phases":506,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":507,"interventions":508},[89],[484,485,486,487,488],[466,490],{"trials":510,"activeCount":99},[],{"trials":512,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":532,"NA":534},{"trials":516,"activeCount":99},[],{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":95,"soonestReadout":39},[523],{"nctId":37,"briefTitle":38,"status":111,"phases":524,"primaryCompletion":39,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},[89],"2026-08","2020-08-06",250,[529],"Prevention of Delirium",[40,531],"Isoflurane + analgesic drug",{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[],{"intervention":531,"totalTrials":95,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":550,"NA":552},{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":95,"soonestReadout":39},[546],{"nctId":37,"briefTitle":38,"status":111,"phases":547,"primaryCompletion":39,"completion":525,"start":526,"enrollment":527,"conditions":548,"interventions":549},[89],[529],[40,531],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":572,"NA":574},{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":95,"soonestReadout":49},[564],{"nctId":47,"briefTitle":48,"status":135,"phases":565,"primaryCompletion":49,"completion":49,"start":566,"enrollment":567,"conditions":568,"interventions":570},[89],"2020-12-22",349,[569],"Non-small-cell Lung Cancer",[50,571],"Pembrolizumab and Chemotherapy drugs",{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":99},[],{"intervention":571,"totalTrials":95,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":590,"NA":592},{"trials":579,"activeCount":99},[],{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":95,"soonestReadout":49},[586],{"nctId":47,"briefTitle":48,"status":135,"phases":587,"primaryCompletion":49,"completion":49,"start":566,"enrollment":567,"conditions":588,"interventions":589},[89],[569],[50,571],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"intervention":595,"totalTrials":95,"cells":596},"high flow oxygen therapy rate adjusted of lung volumes measured",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":615,"NA":617},{"trials":598,"activeCount":99},[],{"trials":600,"activeCount":99},[],{"trials":602,"activeCount":99},[],{"trials":604,"activeCount":95,"soonestReadout":609},[605],{"nctId":606,"briefTitle":607,"status":239,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":614},"NCT06819644","Optimisation of High Flow Oxygen Therapy Settings During Hypoxaemic Respiratory Distress Based on Non-contact Measurement of Lung Volumes by Depth Camera",[89],"2029-05","2025-02",406,[613],"Hypoxemic Respiratory Failure",[595],{"trials":616,"activeCount":99},[],{"trials":618,"activeCount":99},[],{"intervention":620,"totalTrials":95,"cells":621},"Botulinum toxin type A",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":640,"NA":642},{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":95,"soonestReadout":634},[630],{"nctId":631,"briefTitle":632,"status":111,"phases":633,"primaryCompletion":634,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":639},"NCT03198702","Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy",[89],"2027-06","2018-05-17",62,[638],"Obstetrical Brachial Plexus Palsy",[620],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"intervention":645,"totalTrials":95,"cells":646},"Biologic sample",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":99},[],{"trials":658,"activeCount":95,"soonestReadout":663},[659],{"nctId":660,"briefTitle":661,"status":111,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":668},"NCT04297085","Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence",[91],"2050-04","2020-05-28",3400,[667],"Thromboembolic Venous Disease",[645],{"intervention":670,"totalTrials":95,"cells":671},"biological sample",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":95,"soonestReadout":688},[684],{"nctId":685,"briefTitle":686,"status":111,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":690,"conditions":691,"interventions":694},"NCT04207814","Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths",[91],"2057-10-05","2020-10-05",200,[692,693],"Repeated Spontaneous Miscarriages","Fetal Deaths in Utero",[670],{"intervention":696,"totalTrials":95,"cells":697},"Biological samples",{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":95,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":239,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":243,"conditions":716,"interventions":718},"NCT06415422","Platelet Activity Monitoring for Patients Under Adp Medication Using Verify Now in Subdural Hematoma",[91],"2027-02-01","2025-02-01",[717],"Hematoma, Subdural",[696],{"intervention":45,"totalTrials":95,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":95,"soonestReadout":44},[733],{"nctId":42,"briefTitle":43,"status":135,"phases":734,"primaryCompletion":44,"completion":44,"start":735,"enrollment":736,"conditions":737,"interventions":739},[],"2024-11-01",80,[738],"Lateral Epicondylitis",[45],{"intervention":741,"totalTrials":95,"cells":742},"matching genotype with phenotype",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":95,"soonestReadout":759},[755],{"nctId":756,"briefTitle":757,"status":111,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":194,"conditions":761,"interventions":765},"NCT02362685","Metabolic Exercise Testing",[],"2027-12","2008-09",[762,763,764],"Metabolic Myopathies","Exercise Test","Myalgia",[741],{"intervention":166,"totalTrials":95,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":769,"activeCount":99},[],{"trials":771,"activeCount":99},[],{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":95,"soonestReadout":84},[780],{"nctId":82,"briefTitle":83,"status":135,"phases":781,"primaryCompletion":84,"completion":84,"start":162,"enrollment":163,"conditions":782,"interventions":783},[],[140],[80,142,143,166,167],{"intervention":167,"totalTrials":95,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":787,"activeCount":99},[],{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":95,"soonestReadout":84},[798],{"nctId":82,"briefTitle":83,"status":135,"phases":799,"primaryCompletion":84,"completion":84,"start":162,"enrollment":163,"conditions":800,"interventions":801},[],[140],[80,142,143,166,167],{"intervention":803,"totalTrials":95,"cells":804},"Rotateq vaccine",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":827},{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":99},[],{"trials":814,"activeCount":99},[815],{"nctId":816,"briefTitle":817,"status":818,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":826},"NCT00740935","Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.","COMPLETED",[90],"2010-12","2011-06","2007-05",7204,[825],"Rotavirus Gastroenteritis",[803],{"trials":828,"activeCount":99},[],{"intervention":830,"totalTrials":95,"cells":831},"Aspirin",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":853},{"trials":833,"activeCount":99},[],{"trials":835,"activeCount":99},[],{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":99},[],{"trials":841,"activeCount":99},[842],{"nctId":843,"briefTitle":844,"status":845,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT00946907","Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin","TERMINATED",[90],"2011-07","2009-07",34,[851],"Pericarditis",[830],{"trials":854,"activeCount":99},[],{"intervention":856,"totalTrials":168,"cells":857},"Placebos",{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":874,"PHASE4":887,"NA":889},{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":99},[],{"trials":863,"activeCount":99},[864],{"nctId":865,"briefTitle":866,"status":818,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":849,"conditions":870,"interventions":872},"NCT04027101","BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica",[88],"2023-08-30","2020-12-01",[871],"Polymyalgia Rheumatic (PMR)",[873,856],"Baricitinib",{"trials":875,"activeCount":99},[876],{"nctId":877,"briefTitle":878,"status":879,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":849,"conditions":884,"interventions":885},"NCT03632187","Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS","UNKNOWN",[89],"2021-10-21","2022-07-21","2018-12-13",[29],[886,856],"Abatacept",{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[],{"intervention":892,"totalTrials":168,"cells":893},"warfarin",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":922,"NA":924},{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":99},[902,912],{"nctId":903,"briefTitle":904,"status":818,"phases":905,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":911},"NCT00740883","Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. \"PADIS-PE\" Study.",[89],"2015-10","2016-10","2007-07",374,[15],[892],{"nctId":913,"briefTitle":914,"status":818,"phases":915,"primaryCompletion":916,"completion":916,"start":908,"enrollment":917,"conditions":918,"interventions":921},"NCT00740493","Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)",[89],"2017-01",104,[919,920],"Recurrent Venous Thromboembolism","Idiopathic Deep Vein Thrombosis",[892],{"trials":923,"activeCount":99},[],{"trials":925,"activeCount":99},[],{"intervention":927,"totalTrials":95,"cells":928},"enoxaparine 40 mg daily",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":947,"NA":949},{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[937],{"nctId":938,"briefTitle":939,"status":845,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":457,"conditions":944,"interventions":946},"NCT00740545","Prevention of Unexplained Recurrent Abortion by Enoxaparine",[89],"2013-09","2014-09","2007-04",[945],"Alive and Viable Births",[927],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"intervention":952,"totalTrials":95,"cells":953},"Hydroxychloroquine",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":973,"NA":975},{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":99},[962],{"nctId":963,"briefTitle":964,"status":879,"phases":965,"primaryCompletion":966,"completion":54,"start":967,"enrollment":968,"conditions":969,"interventions":972},"NCT03165136","Hydroxychloroquine for Prevention of Recurrent Miscarriage.",[89],"2025-11-01","2017-12-04",300,[970,971],"Recurrent Miscarriage","First Trimester Abortion",[952],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"intervention":978,"totalTrials":95,"cells":979},"Standard diet",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":1000,"NA":1002},{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[988],{"nctId":989,"briefTitle":990,"status":818,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT01267981","Efficacy of Small Bowel Preparation in Capsule Endoscopy",[89],"2016-01","2010-09",858,[996],"Gastrointestinal Bleedings",[978,998,999],"Standard Diet + 500 ml of polyethyleneglycol","Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol",{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"intervention":998,"totalTrials":95,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1018,"NA":1020},{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[1014],{"nctId":989,"briefTitle":990,"status":818,"phases":1015,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":1016,"interventions":1017},[89],[996],[978,998,999],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"intervention":999,"totalTrials":95,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":99},[1032],{"nctId":989,"briefTitle":990,"status":818,"phases":1033,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":1034,"interventions":1035},[89],[996],[978,998,999],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"intervention":1041,"totalTrials":95,"cells":1042},"Oxybutynin",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1061,"NA":1063},{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":99},[],{"trials":1048,"activeCount":99},[],{"trials":1050,"activeCount":99},[1051],{"nctId":1052,"briefTitle":1053,"status":818,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":636,"conditions":1058,"interventions":1060},"NCT01855256","Treatment of Hyperhidrosis With Oxybutynin",[89],"2014-02","2014-03","2013-06",[1059],"Hyperhidrosis",[1041],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[],{"intervention":1066,"totalTrials":95,"cells":1067},"bumetanide",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1085,"NA":1087},{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":99},[1076],{"nctId":1077,"briefTitle":1078,"status":818,"phases":1079,"primaryCompletion":821,"completion":821,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT01078714","Efficiency of Bumetanide in Autistic Children",[89],"2010-03",60,[1083],"Autistics Children",[1066],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[],{"intervention":1090,"totalTrials":95,"cells":1091},"Ibuprofen",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1108,"NA":1110},{"trials":1093,"activeCount":99},[],{"trials":1095,"activeCount":99},[],{"trials":1097,"activeCount":99},[],{"trials":1099,"activeCount":99},[1100],{"nctId":1101,"briefTitle":1102,"status":845,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":124,"conditions":1106,"interventions":1107},"NCT02839785","Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP)",[89],"2018-09-19","2017-03-29",[34],[1090],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"intervention":1113,"totalTrials":95,"cells":1114},"Aprepitant 80 mg",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1136,"NA":1138},{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":99},[],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[1123],{"nctId":1124,"briefTitle":1125,"status":818,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1134},"NCT03808805","Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms",[89],"2023-09-01","2024-08-22","2019-04-16",63,[1132,1133],"Myeloproliferative Disorder","Aquagenic Pruritus",[1113,1135],"Hydroxyzine 25mg",{"trials":1137,"activeCount":99},[],{"trials":1139,"activeCount":99},[],{"intervention":1135,"totalTrials":95,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1154,"NA":1156},{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[1150],{"nctId":1124,"briefTitle":1125,"status":818,"phases":1151,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1152,"interventions":1153},[89],[1132,1133],[1113,1135],{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":99},[],{"intervention":1159,"totalTrials":95,"cells":1160},"Pre-therapeutic imaging test",{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1181,"NA":1183},{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":99},[],{"trials":1168,"activeCount":99},[1169],{"nctId":1170,"briefTitle":1171,"status":879,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1081,"conditions":1176,"interventions":1180},"NCT04942275","Lung Perfusion PET \u002F CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy",[88,89],"2022-07-30","2023-09-30","2021-07-15",[1177,1178,1179],"SBRT","Non-small Cell Lung Cancer","Lung Metastasis",[1159],{"trials":1182,"activeCount":99},[],{"trials":1184,"activeCount":99},[],{"intervention":1186,"totalTrials":95,"cells":1187},"Exacyl®",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1206,"NA":1208},{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[1196],{"nctId":1197,"briefTitle":1198,"status":818,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT02403596","Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban",[89],"2017-08-29","2015-10-20",231,[1204],"Blood Loss After a Total Hip Replacement",[1186],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"intervention":1211,"totalTrials":95,"cells":1212},"impact on VASP test",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1231,"NA":1233},{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[],{"trials":1220,"activeCount":99},[1221],{"nctId":1222,"briefTitle":1223,"status":818,"phases":1224,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1230},"NCT00349661","Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel",[89],"2006-12","2006-06",120,[1229],"Coronary Heart Disease",[1211],{"trials":1232,"activeCount":99},[],{"trials":1234,"activeCount":99},[],{"intervention":1236,"totalTrials":95,"cells":1237},"Reduced dose of DOAC",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1256,"NA":1258},{"trials":1239,"activeCount":99},[],{"trials":1241,"activeCount":99},[],{"trials":1243,"activeCount":99},[],{"trials":1245,"activeCount":99},[1246],{"nctId":1247,"briefTitle":1248,"status":818,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1254},"NCT03285438","REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.",[89],"2023-11-08","2017-11-02",2774,[18],[1236,1255],"Full dose of DOAC",{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[],{"intervention":1255,"totalTrials":95,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[],{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":99},[1270],{"nctId":1247,"briefTitle":1248,"status":818,"phases":1271,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1272,"interventions":1273},[89],[18],[1236,1255],{"trials":1275,"activeCount":99},[],{"trials":1277,"activeCount":99},[],{"intervention":1279,"totalTrials":95,"cells":1280},"Insulin Aspart",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1299,"NA":1301},{"trials":1282,"activeCount":99},[],{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[1289],{"nctId":1290,"briefTitle":1291,"status":818,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1298},"NCT02546401","Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump",[89],"2016-03","2015-09",22,[1297],"Diabetes Type 1",[1279],{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"intervention":1304,"totalTrials":95,"cells":1305},"Rosuvastatin",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1312,"PHASE4":1325,"NA":1327},{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[1314],{"nctId":1315,"briefTitle":1316,"status":845,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},"NCT01494090","Statin in Hip Fracture",[89],"2012-03","2012-09","2011-08",36,[1323],"Hip Fracture",[1304],{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":99},[],{"intervention":1330,"totalTrials":95,"cells":1331},"Anti R-IL2 + Cyclosporine",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1352,"NA":1354},{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[1340],{"nctId":1341,"briefTitle":1342,"status":818,"phases":1343,"primaryCompletion":1056,"completion":1344,"start":1345,"enrollment":1346,"conditions":1347,"interventions":1349},"NCT01028092","mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation",[89],"2014-07","2009-03",327,[1348],"Renal Transplant",[1330,1350,1351],"Thymoglobulin + Everolimus","Anti R-IL2 + Cyclosporine then Everolimus",{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[],{"intervention":1350,"totalTrials":95,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1370,"NA":1372},{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[],{"trials":1365,"activeCount":99},[1366],{"nctId":1341,"briefTitle":1342,"status":818,"phases":1367,"primaryCompletion":1056,"completion":1344,"start":1345,"enrollment":1346,"conditions":1368,"interventions":1369},[89],[1348],[1330,1350,1351],{"trials":1371,"activeCount":99},[],{"trials":1373,"activeCount":99},[],{"intervention":1351,"totalTrials":95,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1388,"NA":1390},{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[1384],{"nctId":1341,"briefTitle":1342,"status":818,"phases":1385,"primaryCompletion":1056,"completion":1344,"start":1345,"enrollment":1346,"conditions":1386,"interventions":1387},[89],[1348],[1330,1350,1351],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"intervention":1393,"totalTrials":95,"cells":1394},"OAC + Aspirin 100mg od",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1401,"PHASE4":1414,"NA":1416},{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":99},[],{"trials":1402,"activeCount":99},[1403],{"nctId":1404,"briefTitle":1405,"status":845,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT04217447","Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease",[89],"2024-10-28","2020-05-25",874,[1411],"Coronary Artery Disease",[1393,1413],"OAC + placebo of Aspirin 100mg od",{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"intervention":1413,"totalTrials":95,"cells":1419},{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1432,"NA":1434},{"trials":1421,"activeCount":99},[],{"trials":1423,"activeCount":99},[],{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[1428],{"nctId":1404,"briefTitle":1405,"status":845,"phases":1429,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1430,"interventions":1431},[89],[1411],[1393,1413],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"intervention":1437,"totalTrials":95,"cells":1438},"Rituximab (mabthera)",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1458,"NA":1460},{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[1447],{"nctId":1448,"briefTitle":1449,"status":818,"phases":1450,"primaryCompletion":1451,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1457},"NCT00740948","Tolerance and Efficacy of Rituximab in Sjogren's Disease",[88,89],"2012-01","2013-01","2008-03",122,[1456],"Sjogren's Disease",[1437],{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[],{"intervention":886,"totalTrials":95,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1476,"NA":1478},{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[1472],{"nctId":877,"briefTitle":878,"status":879,"phases":1473,"primaryCompletion":881,"completion":882,"start":883,"enrollment":849,"conditions":1474,"interventions":1475},[89],[29],[886,856],{"trials":1477,"activeCount":99},[],{"trials":1479,"activeCount":99},[],{"intervention":1481,"totalTrials":95,"cells":1482},"Varenicline",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1502,"NA":1504},{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[1491],{"nctId":1492,"briefTitle":1493,"status":818,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1501},"NCT01694732","Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease",[89],"2015-11","2012-08",83,[26,1499,1500],"COPD Exacerbation","Smoking",[1481],{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"intervention":1507,"totalTrials":95,"cells":1508},"lidocaïne\u002Fprilocaïne 5%",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1526,"NA":1528},{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[1517],{"nctId":1518,"briefTitle":1519,"status":818,"phases":1520,"primaryCompletion":906,"completion":906,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1525},"NCT01964248","Local Anesthesia Before Arterial Puncture for Blood Gas Analysis",[89],"2012-12",136,[1524],"Indication of Blood Gas Analysis by Radial Artery Blood Sampling",[1507],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"intervention":1531,"totalTrials":95,"cells":1532},"Spironolactone",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1550,"NA":1552},{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[1541],{"nctId":1542,"briefTitle":1543,"status":818,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1057,"enrollment":1546,"conditions":1547,"interventions":1549},"NCT01848639","ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial",[89],"2022-11",823,[1548],"End Stage Renal Failure on Dialysis",[1531],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"intervention":1555,"totalTrials":95,"cells":1556},"Xylocaine",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1575,"NA":1577},{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[1565],{"nctId":1566,"briefTitle":1567,"status":818,"phases":1568,"primaryCompletion":1569,"completion":821,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1574},"NCT01216488","Comparison Between Two Different Volumes of Anesthesia Drug in Forearm Surgery",[89],"2010-06","2010-01",72,[1573],"Forearm and Arm Surgery",[1555],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"intervention":1580,"totalTrials":95,"cells":1581},"Enoxaparin",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1600,"NA":1602},{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[1590],{"nctId":1591,"briefTitle":1592,"status":818,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT02379806","The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study",[89],"2020-12","2020-12-29","2015-09-03",2560,[18],[1580],{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"intervention":1605,"totalTrials":95,"cells":1606},"Dexmedetomidine",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1626,"NA":1628},{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[],{"trials":1614,"activeCount":99},[1615],{"nctId":1616,"briefTitle":1617,"status":818,"phases":1618,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1624},"NCT03477344","Dexmedetomidine After Cardiac Surgery for Prevention of Delirium",[89],"2021-06-29","2019-01-04",348,[1623],"ICU Delirium",[1605,1625],"Sodium chloride 0.9%",{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"intervention":1625,"totalTrials":95,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1644,"NA":1646},{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[1640],{"nctId":1616,"briefTitle":1617,"status":818,"phases":1641,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1642,"interventions":1643},[89],[1623],[1605,1625],{"trials":1645,"activeCount":99},[],{"trials":1647,"activeCount":99},[],{"intervention":1649,"totalTrials":168,"cells":1650},"Vinorelbine",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[1657,1666],{"nctId":1658,"briefTitle":1659,"status":818,"phases":1660,"completion":1661,"start":1662,"enrollment":1081,"conditions":1663,"interventions":1665},"NCT00295672","Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.",[88],"2007-06","2006-02",[1664],"Lung Neoplasm",[1649],{"nctId":1667,"briefTitle":1668,"status":818,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":736,"conditions":1673,"interventions":1674},"NCT03801304","Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer",[88],"2021-01-04","2022-02-23","2019-01-24",[1178],[1675,1649],"Atezolizumab",{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[],{"intervention":1683,"totalTrials":95,"cells":1684},"Roscovitine",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[1691],{"nctId":1692,"briefTitle":1693,"status":845,"phases":1694,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1699},"NCT02649751","Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",[88],"2018-07-26","2016-02-22",49,[21],[1683],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[],{"intervention":1707,"totalTrials":95,"cells":1708},"TCZ",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"trials":1714,"activeCount":99},[1715],{"nctId":1716,"briefTitle":1717,"status":818,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT01713842","Tocilizumab Effect iN pOlymyalgia Rheumatica",[88],"2014-10","2012-07",21,[29],[1707],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[],{"intervention":1731,"totalTrials":95,"cells":1732},"Pemetrexed, cisplatin",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[1739],{"nctId":1740,"briefTitle":1741,"status":818,"phases":1742,"start":760,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT00744900","Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)",[88],45,[1745],"Lung Cancer",[1731],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[],{"intervention":1675,"totalTrials":95,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[1761],{"nctId":1667,"briefTitle":1668,"status":818,"phases":1762,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":736,"conditions":1763,"interventions":1764},[88],[1178],[1675,1649],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"intervention":873,"totalTrials":95,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[1779],{"nctId":865,"briefTitle":866,"status":818,"phases":1780,"primaryCompletion":868,"completion":868,"start":869,"enrollment":849,"conditions":1781,"interventions":1782},[88],[871],[873,856],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"intervention":1790,"totalTrials":95,"cells":1791},"infusion of MYOCET",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[1798],{"nctId":1799,"briefTitle":1800,"status":845,"phases":1801,"primaryCompletion":1802,"completion":1802,"start":1803,"enrollment":1804,"conditions":1805,"interventions":1807},"NCT01848652","Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and \u002F or High-dose Cytarabine.",[88],"2015-05","2013-10",5,[1806],"Cerebral Lymphoma B Cell Refractory",[1790],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"intervention":1815,"totalTrials":95,"cells":1816},"rivaroxaban 20 mg once daily 8 days",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1833,"PHASE3":1835,"PHASE4":1837,"NA":1839},{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":99},[1821],{"nctId":1822,"briefTitle":1823,"status":818,"phases":1824,"primaryCompletion":1825,"completion":1826,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1832},"NCT04180436","Pharmacokinetics of Rivaroxaban After Bariatric Surgery",[87],"2022-06-21","2022-06-27","2020-01-15",67,[1830,1831],"Bariatric Surgery","Morbid Obesity",[1815],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[],{"trials":1838,"activeCount":99},[],{"trials":1840,"activeCount":99},[],{"intervention":1842,"totalTrials":168,"cells":1843},"Tocilizumab",{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1850,"PHASE4":1861,"NA":1863},{"trials":1845,"activeCount":99},[],{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[1852],{"nctId":1853,"briefTitle":1854,"status":818,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1860},"NCT02908217","Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE",[89],"2020-11-12","2017-02-15",113,[29],[1842],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[1865],{"nctId":1866,"briefTitle":1867,"status":818,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":243,"conditions":1871,"interventions":1872},"NCT02888496","Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica",[],"2015-06","2015-01",[29],[1873],"tocilizumab",{"intervention":1875,"totalTrials":95,"cells":1876},"Pentoxifylline-Tocopherol-Clodronate",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[1889],{"nctId":1890,"briefTitle":1891,"status":818,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1898},"NCT04097847","Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study",[],"2019-04-01","2017-06-02",96,[1897],"Osteoradionecrosis of Jaw",[1875],{"intervention":1900,"totalTrials":95,"cells":1901},"Genetic sample",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[1914],{"nctId":1915,"briefTitle":1916,"status":818,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":1920,"conditions":1921,"interventions":1922},"NCT02841085","New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study \"FIT GENETIQUE\".",[],"2021-05-14","2010-05-27",613,[667],[1900],{"intervention":1924,"totalTrials":95,"cells":1925},"somatic cytogenetic and genetic characterization",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[],{"trials":1935,"activeCount":99},[],{"trials":1937,"activeCount":99},[1938],{"nctId":1939,"briefTitle":1940,"status":879,"phases":1941,"primaryCompletion":1942,"completion":1174,"start":1943,"enrollment":1944,"conditions":1945,"interventions":1949},"NCT04701229","Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes",[],"2022-09-30","2020-09-30",100,[1946,1947,1948],"Myelodysplastic Syndromes","Myelodysplastic Syndrome With Isolated Del(5Q)","Myelodysplastic Syndrome With Del(5Q)",[1924],{"intervention":1951,"totalTrials":95,"cells":1952},"Thymoglobulin Induction",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1954,"activeCount":99},[],{"trials":1956,"activeCount":99},[],{"trials":1958,"activeCount":99},[],{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[],{"trials":1964,"activeCount":99},[1965],{"nctId":1966,"briefTitle":1967,"status":879,"phases":1968,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":243,"conditions":1971,"interventions":1972},"NCT02894606","Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients",[],"2018-02","2015-02",[1348],[1951,1973],"Basiliximab Induction",{"intervention":1973,"totalTrials":95,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[1988],{"nctId":1966,"briefTitle":1967,"status":879,"phases":1989,"primaryCompletion":1969,"completion":1969,"start":1970,"enrollment":243,"conditions":1990,"interventions":1991},[],[1348],[1951,1973],{"intervention":1993,"totalTrials":95,"cells":1994},"Checkpoint inhibitor therapy",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[2007],{"nctId":2008,"briefTitle":2009,"status":818,"phases":2010,"primaryCompletion":2011,"completion":2011,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2017},"NCT03140137","Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases",[],"2018-01-04","2017-01-21",112,[2015,2016],"Autoimmune Diseases","Advanced Cancer",[1993],{"intervention":2019,"totalTrials":95,"cells":2020},"Reticera",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[2033],{"nctId":2034,"briefTitle":2035,"status":845,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2043},"NCT02832323","Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera Hemodialysis Population",[91],"2021-06-20","2021-06-30","2016-06-22",94,[2042],"Renal Insufficiency, Chronic",[2019],{"intervention":2045,"totalTrials":95,"cells":2046},"Filgrastim Prefilled Syringe [Zarzio®]",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[],{"trials":2058,"activeCount":99},[2059],{"nctId":2060,"briefTitle":2061,"status":818,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":2064,"enrollment":636,"conditions":2065,"interventions":2069},"NCT03323541","Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure",[],"2016-12-31","2016-11-03",[2066,2067,2068],"Multiple Myeloma","Non-hodgkin Lymphoma","Hodgkin Lymphoma",[2045],{"intervention":2071,"totalTrials":95,"cells":2072},"Chlorpromazine or Pentobarbital",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[],{"trials":2080,"activeCount":99},[],{"trials":2082,"activeCount":99},[],{"trials":2084,"activeCount":99},[2085],{"nctId":2086,"briefTitle":2087,"status":879,"phases":2088,"primaryCompletion":2089,"completion":2089,"start":2090,"enrollment":2091,"conditions":2092,"interventions":2094},"NCT04350528","Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures",[],"2020-06-30","2020-04-30",254,[2093],"Children Sedation",[2071],{"intervention":2096,"totalTrials":95,"cells":2097},"blood samples",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[2110],{"nctId":2111,"briefTitle":2112,"status":818,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2120},"NCT04253275","Identification of Biomarkers in Ischemic Stroke - Clinical Trial",[91],"2024-02-06","2020-11-24",61,[2118,2119],"Stroke, Ischemic","Stroke Hemorrhagic",[2096],{"intervention":2122,"totalTrials":95,"cells":2123},"Biological tests",{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2125,"activeCount":99},[],{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"trials":2131,"activeCount":99},[],{"trials":2133,"activeCount":99},[],{"trials":2135,"activeCount":99},[2136],{"nctId":2137,"briefTitle":2138,"status":818,"phases":2139,"primaryCompletion":1294,"completion":1294,"start":1870,"enrollment":1321,"conditions":2140,"interventions":2143},"NCT02891109","Regulatory B Cells and Chronic Immune Thrombocytopenia",[],[2141,2142],"Purpura, Thrombocytopenic, Idiopathic","Regulatory B Cells",[2122],{"intervention":2145,"totalTrials":95,"cells":2146},"Sampling of blood",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[2159],{"nctId":2160,"briefTitle":2161,"status":818,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2168},"NCT02008552","Study of the Effect of the Benfluorex",[91],"2021-10-18","2013-10-18",346,[2167],"Blood Sample",[2145],{"intervention":2170,"totalTrials":95,"cells":2171},"Patients with antifungal prophylaxis",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":2185,"briefTitle":2186,"status":818,"phases":2187,"primaryCompletion":2188,"completion":2188,"start":2189,"enrollment":2190,"conditions":2191,"interventions":2194},"NCT02900430","Invasives Aspergillosis in Acute Myeloid Leukemia",[],"2015-12","2009-01",246,[2192,2193],"Acute Myeloid Leukemia","Invasive Aspergillosis",[2170]]